Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$3.15 +3.6%	$2.89	$2.56 ▼ $6.44	$591.20M	0.25	4.31 million shs	7.97 million shs
INSP Inspire Medical Systems	$45.56 +2.1%	$44.81	$38.91 ▼ $147.03	$1.29B	0.71	1.01 million shs	1.35 million shs
LLY Eli Lilly and Company	$1,192.16 -0.6%	$1,053.61	$623.78 ▼ $1,238.00	$1.13T	0.51	3.32 million shs	2.72 million shs
NVO Novo Nordisk A/S	$48.69 +1.6%	$44.25	$35.12 ▼ $71.79	$214.05B	0.77	12.74 million shs	11.18 million shs
VKTX Viking Therapeutics	$37.48 -3.9%	$31.78	$22.96 ▼ $43.15	$4.53B	0.66	2.70 million shs	3.10 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	+2.89%	+3.95%	-0.82%	-3.04%	-21.83%
INSP Inspire Medical Systems	-0.60%	+7.44%	+7.83%	-16.66%	-65.42%
LLY Eli Lilly and Company	-2.20%	+8.01%	+8.50%	+25.52%	+53.88%
NVO Novo Nordisk A/S	-0.91%	+1.14%	+5.15%	+31.49%	-30.61%
VKTX Viking Therapeutics	-1.34%	+12.07%	+19.15%	+18.36%	+47.21%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$3.15 +3.6%	$2.89	$2.56 ▼ $6.44	$591.20M	0.25	4.31 million shs	7.97 million shs
INSP Inspire Medical Systems	$45.56 +2.1%	$44.81	$38.91 ▼ $147.03	$1.29B	0.71	1.01 million shs	1.35 million shs
LLY Eli Lilly and Company	$1,192.16 -0.6%	$1,053.61	$623.78 ▼ $1,238.00	$1.13T	0.51	3.32 million shs	2.72 million shs
NVO Novo Nordisk A/S	$48.69 +1.6%	$44.25	$35.12 ▼ $71.79	$214.05B	0.77	12.74 million shs	11.18 million shs
VKTX Viking Therapeutics	$37.48 -3.9%	$31.78	$22.96 ▼ $43.15	$4.53B	0.66	2.70 million shs	3.10 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	+2.89%	+3.95%	-0.82%	-3.04%	-21.83%
INSP Inspire Medical Systems	-0.60%	+7.44%	+7.83%	-16.66%	-65.42%
LLY Eli Lilly and Company	-2.20%	+8.01%	+8.50%	+25.52%	+53.88%
NVO Novo Nordisk A/S	-0.91%	+1.14%	+5.15%	+31.49%	-30.61%
VKTX Viking Therapeutics	-1.34%	+12.07%	+19.15%	+18.36%	+47.21%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.55	Moderate Buy	$15.71	398.87% Upside
INSP Inspire Medical Systems	2.05	Hold	$81.05	77.91% Upside
LLY Eli Lilly and Company	2.87	Moderate Buy	$1,235.07	3.60% Upside
NVO Novo Nordisk A/S	2.17	Hold	$65.56	34.66% Upside
VKTX Viking Therapeutics	2.79	Moderate Buy	$93.60	149.73% Upside

Current Analyst Ratings Breakdown

Latest LLY, NVO, VKTX, ALT, and INSP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2026	LLY Eli Lilly and Company	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$1,119.00 ➝ $1,232.00
6/24/2026	ALT Altimmune	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/23/2026	INSP Inspire Medical Systems	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$40.00
6/22/2026	LLY Eli Lilly and Company	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
6/22/2026	ALT Altimmune	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
6/22/2026	LLY Eli Lilly and Company	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$1,050.00 ➝ $1,135.00
6/19/2026	NVO Novo Nordisk A/S	Nordea Equity Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy
6/15/2026	LLY Eli Lilly and Company	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
6/15/2026	INSP Inspire Medical Systems	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
6/15/2026	INSP Inspire Medical Systems	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sector Perform ➝ Buy
6/9/2026	LLY Eli Lilly and Company	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$1,330.00 ➝ $1,350.00

(Data available from 7/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$40K	15,314.51	N/A	N/A	$1.99 per share	1.58
INSP Inspire Medical Systems	$911.98M	1.44	$2.92 per share	15.58	$26.88 per share	1.69
LLY Eli Lilly and Company	$65.18B	17.22	$24.99 per share	47.71	$28.07 per share	42.47
NVO Novo Nordisk A/S	$46.80B	4.65	$4.76 per share	10.23	$6.58 per share	7.40
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$5.65 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$88.09M	-$0.93	N/A	N/A	N/A	-214,860.98%	-42.57%	-35.57%	8/11/2026 (Estimated)
INSP Inspire Medical Systems	$145.42M	$4.49	10.15	31.86	4.52	14.33%	10.35%	8.81%	8/3/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$28.15	42.35	26.74	1.49	34.98%	105.77%	23.76%	8/5/2026 (Estimated)
NVO Novo Nordisk A/S	$15.51B	$4.26	11.43	14.62	4.33	37.23%	63.31%	22.19%	8/5/2026 (Estimated)
VKTX Viking Therapeutics	-$359.64M	-$4.14	N/A	N/A	N/A	N/A	-71.31%	-65.35%	7/29/2026 (Estimated)

Latest LLY, NVO, VKTX, ALT, and INSP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/29/2026	Q2 2026	VKTX Viking Therapeutics	-$1.21	N/A	N/A	N/A	N/A	N/A
5/13/2026	Q1 2026	ALT Altimmune	-$0.25	-$0.18	+$0.07	-$0.18	$0.00 million	N/A
5/6/2026	Q1 2026	NVO Novo Nordisk A/S	$0.87	$1.04	+$0.17	$1.69	$10.86 billion	$10.85 billion
5/4/2026	Q1 2026	INSP Inspire Medical Systems	-$0.2753	$0.10	+$0.3753	-$0.39	$200.04 million	$204.58 million
4/30/2026	Q1 2026	LLY Eli Lilly and Company	$6.97	$8.55	+$1.58	$8.26	$17.82 billion	$19.80 billion
4/30/2026	Q1 2026	VKTX Viking Therapeutics	-$1.01	-$1.37	-$0.36	-$1.37	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
INSP Inspire Medical Systems	N/A	N/A	N/A	N/A	N/A
LLY Eli Lilly and Company	$6.92	0.58%	+15.18%	24.58%	11 Years
NVO Novo Nordisk A/S	$1.75	3.59%	+21.74%	41.08%	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest LLY, NVO, VKTX, ALT, and INSP Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/22/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.63%	8/14/2026	8/14/2026	9/10/2026
5/4/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.69%	5/15/2026	5/15/2026	6/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	0.12	29.56	29.56
INSP Inspire Medical Systems	N/A	6.34	4.48
LLY Eli Lilly and Company	1.26	1.50	1.10
NVO Novo Nordisk A/S	0.59	0.79	0.56
VKTX Viking Therapeutics	N/A	5.72	5.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
INSP Inspire Medical Systems	94.91%
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	1.60%
INSP Inspire Medical Systems	2.20%
LLY Eli Lilly and Company	0.14%
NVO Novo Nordisk A/S	0.07%
VKTX Viking Therapeutics	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	50	194.47 million	191.36 million	Optionable
INSP Inspire Medical Systems	1,333	28.81 million	28.18 million	Optionable
LLY Eli Lilly and Company	50,000	941.74 million	940.42 million	Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable
VKTX Viking Therapeutics	20	116.11 million	109.95 million	Optionable

LLY, NVO, VKTX, ALT, and INSP Headlines

Recent News About These Companies

Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

2 hours ago | zacks.com

Is Viking Therapeutics Stock Going to $100?

4 hours ago | fool.com

Novo Nordisk vs. Viking: Which Obesity Drug Stock Is the Better Buy?

June 29 at 12:11 PM | zacks.com

Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?

June 29 at 11:51 AM | finance.yahoo.com

Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?

June 29 at 10:31 AM | zacks.com

Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN) and Viking Therapeutics (VKTX)

June 26, 2026 | theglobeandmail.com

Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

June 26, 2026 | fool.com

Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

June 25, 2026 | finance.yahoo.com

Viking Therapeutics (VKTX) Starts First Human Obesity Trial For VK3019

June 25, 2026 | finance.yahoo.com

Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

June 25, 2026 | zacks.com

VKTX Stock Jumps on Phase I Study Initiation for New Obesity Drug

June 25, 2026 | finance.yahoo.com

VKTX Stock Jumps on Phase I Study Initiation for New Obesity Drug

June 25, 2026 | zacks.com

VKTX Stock On Track For Five Consecutive Days Of Gains — Viking Launches Human Trial For Novel Obesity Drug VK3019

June 24, 2026 | stocktwits.comS

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

June 24, 2026 | finance.yahoo.com

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

June 24, 2026 | prnewswire.com

Viking Therapeutics (VKTX) Soars Higher — Medicare Could Hold The Answer

June 24, 2026 | finance.yahoo.com

3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal

June 23, 2026 | 247wallst.com

Is Viking Therapeutics Stock a No-Brainer Buy Below $35?

June 22, 2026 | fool.com

Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk

June 22, 2026 | fool.com

Set It and Forget It: 2 Consumer Stocks to Hold for the Next 20 Years

June 22, 2026 | fool.com

Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge

...

May 1, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LLY, NVO, VKTX, ALT, and INSP Company Descriptions

Altimmune NASDAQ:ALT

$3.15 +0.11 (+3.62%)

Closing price 04:00 PM Eastern

Extended Trading

$3.18 +0.02 (+0.79%)

As of 07:52 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Inspire Medical Systems NYSE:INSP

$45.56 +0.95 (+2.13%)

Closing price 03:59 PM Eastern

Extended Trading

$46.00 +0.44 (+0.97%)

As of 07:53 PM Eastern

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

Eli Lilly and Company NYSE:LLY

$1,192.16 -7.27 (-0.61%)

Closing price 03:59 PM Eastern

Extended Trading

$1,189.56 -2.61 (-0.22%)

As of 07:59 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S NYSE:NVO

$48.69 +0.75 (+1.56%)

Closing price 03:59 PM Eastern

Extended Trading

$48.56 -0.12 (-0.25%)

As of 07:59 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Viking Therapeutics NASDAQ:VKTX

$37.48 -1.53 (-3.92%)

Closing price 04:00 PM Eastern

Extended Trading

$37.42 -0.06 (-0.16%)

As of 07:59 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LLY, NVO, VKTX, ALT, and INSP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LLY, NVO, VKTX, ALT, and INSP Earnings

Compare Dividends

Latest LLY, NVO, VKTX, ALT, and INSP Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LLY, NVO, VKTX, ALT, and INSP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LLY, NVO, VKTX, ALT, and INSP Company Descriptions

Altimmune NASDAQ:ALT

Inspire Medical Systems NYSE:INSP

Eli Lilly and Company NYSE:LLY

Novo Nordisk A/S NYSE:NVO

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools